Vernalis Overview
- Year Founded
-
1986
- Status
-
Acquired/Merged
- Employees
-
80
- Latest Deal Type
-
M&A
- Financing Rounds
-
10
- Investments
-
6
Vernalis General Information
Description
Developer of bio-medical products created for the treatment of several diseases based in Cambridge, United Kingdom. The company's research laboratories integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modeling with extensive medicinal chemistry expertise, thereby enabling drug discovery on both established and novel targets.
Contact Information
Website
www.vernalis.com(Operating Subsidiary)
Corporate Office
- Granta Park Great Abington
- Cambridge CB21 6GB
- England, United Kingdom
Corporate Office
- Granta Park Great Abington
- Cambridge CB21 6GB
- England, United Kingdom
Vernalis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vernalis Comparisons
Industry
Financing
Details
Vernalis Competitors (42)
One of Vernalis’s 42 competitors is Mission Therapeutics, a Venture Capital-Backed company based in Cambridge, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mission Therapeutics | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Metrion Biosciences | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Aviva Systems Biology | Formerly VC-backed | San Diego, CA |
Vernalis Patents
Vernalis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026229590-A1 | Polycyclic derivatives, pharmaceutical compositions containing them, their combination with one or more anti-cancer agents, and their uses as pro-apoptotic agents | Pending | 30-Apr-2025 | ||
| AU-2025254981-A1 | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors | Pending | 10-Apr-2024 | ||
| WO-2025215110-A1 | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors | Pending | 10-Apr-2024 | ||
| AU-2025213763-A1 | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors | Pending | 31-Jan-2024 | ||
| WO-2025163050-A1 | New amide derivatives, pharmaceutical compositions containing them and their uses as sos1 inhibitors | Pending | 31-Jan-2024 | C07D405/14 |
Vernalis Signals
Vernalis Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vernalis Investments & Acquisitions (6)
Vernalis’s most recent deal was a Seed Round with Unison Medicines. The deal was made on 09-Mar-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Unison Medicines | 09-Mar-2022 | Seed Round | Drug Discovery | ||
| Dania Therapeutics | 31-Oct-2021 | Joint Venture | Drug Discovery | ||
| Cita NeuroPharmaceutical | 18-Nov-2005 | Merger/Acquisition | Biotechnology | ||
| Pintex Pharmaceuticals | 01-Apr-2005 | Merger/Acquisition | Pharmaceuticals | ||
| British Biotech | 03-Jul-2003 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Vernalis FAQs
-
When was Vernalis founded?
Vernalis was founded in 1986.
-
Where is Vernalis headquartered?
Vernalis is headquartered in Cambridge, United Kingdom.
-
What is the size of Vernalis?
Vernalis has 80 total employees.
-
What industry is Vernalis in?
Vernalis’s primary industry is Biotechnology.
-
Is Vernalis a private or public company?
Vernalis is a Private company.
-
What is the current valuation of Vernalis?
The current valuation of Vernalis is .
-
What is Vernalis’s current revenue?
The current revenue for Vernalis is .
-
How much funding has Vernalis raised over time?
Vernalis has raised $195M.
-
Who are Vernalis’s investors?
Apax Nominees, BVF Partners, Domain Associates, HarbourVest Partners, and Invesco are 5 of 12 investors who have invested in Vernalis.
-
Who are Vernalis’s competitors?
Mission Therapeutics, Metrion Biosciences, Sygnature Discovery, Genetix Biotherapeutics, and Aviva Systems Biology are some of the 42 competitors of Vernalis.
-
When was Vernalis acquired?
Vernalis was acquired on 02-Dec-2020.
-
Who acquired Vernalis?
Vernalis was acquired by HitGen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process